参松养心胶囊治疗脑干出血并发脑心综合征伴心律失常的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 参松养心胶囊治疗脑干出血并发脑心综合征伴心律失常的临床观察
TITLE:
摘要: 目的:观察参松养心胶囊治疗脑干出血并发脑心综合征(CCS)伴心律失常的疗效和安全性。方法:回顾性分析98例脑干出血并发CCS伴心律失常患者资料,按用药的不同分为对照组(49例)和观察组(49例)。对照组患者给予甘露醇、吡拉西坦等常规治疗;观察组患者在对照组治疗的基础上给予参松养心胶囊1.2 g,口服或鼻饲,每日3次。两组疗程均为4周。观察两组患者的临床疗效,治疗前后儿茶酚胺水平[去甲肾上腺素(NE)、肾上腺素(E)、多巴胺(DA)]、内皮素1(ET-1)、一氧化氮(NO)水平及不良反应发生情况。结果:观察组患者总有效率显著高于对照组(75.51% vs. 46.93%),差异有统计学意义(P<0.05)。治疗前,两组患者NE、E、DA、ET-1、NO水平比较,差异均无统计学意义(P>0.05)。治疗后3、7 d,两组患者NE、E、DA、ET-1、NO水平均显著低于同组治疗前,且观察组显著低于对照组,差异均有统计学意义(P<0.05) 。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:在常规治疗的基础上,参松养心胶囊治疗脑干出血并发CCS伴心律失常的疗效显著,可降低儿茶酚胺水平,且未增加不良反应的发生。
ABSTRACT: OBJECTIVE: To observe therapeutic efficacy and safety of Shensong yangxin capsules in the treatment of brainsten hemorrhage complicated with cerebrocardiac syndrome (CCS) accompanied by arrhythmia. METHODS: Medical information of 98 patients with brainstem hemorrhage complicated with CCS arrhythmia were analyzed retrospectively and divided into control group (49 cases) and observation group (49 cases) according to drug use. Control group was given routine treatment as mannitol and piracetam. Observation group was additionally given Shensong yangxin capsules 1.2 g orally or via nasal feeding, 3 times a day, on the basis of control group. Treatment course of 2 groups lasted for 4 weeks. Clinical efficacies of 2 groups were observed as well as the levels of catecholamine [norepinephrine (NE), epinephrine (E), dopamine (DA)], ET-1 and NO, the occurrence of ADR before and after treatment. RESULTS: Total response rate of observation group was significantly higher than that of control group(75.5% vs. 46.93%), with statistical significance (P<0.05). Before treatment, there was no statistical significance in the levels of NE, E,DA,ET-1 and NO between 2 groups(P>0.05). 3 and 7 d after treatment, the levels of NE, E, DA, ET-1 and NO in 2 groups were significantly lower than before, and the observation group was significantly lower than the control group, with statistical significance (P<0.05). There was no statistical significance in the incidence of ADR between 2 groups (P>0.05). CONCLUSIONS: Based on routine treatment, Shensong yangxin capsules shows significant therapeutic efficacy for CCS, can reduce levels of catecholamine and doesn’t increase the occurrence of ADR.
期刊: 2017年第28卷第18期
作者: 李伟,刘晓婷,李佳,李敬,许雪英,杨君
AUTHORS: LI Wei,LIU Xiaoting,LI Jia,LI Jing,XU Xueying,YANG Jun
关键字: 脑干出血;脑心综合征;心律失常;参松养心胶囊;儿茶酚胺;疗效;安全性
KEYWORDS: Brainstem hemorrhage; Cerebrocardiac syndrome; Arrhythmia; Shensong yangxin capsules; Catecholamine; Therapeutic efficacy; Safety
阅读数: 526 次
本月下载数: 2 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!